Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H2 2016, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape. Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 2 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 4 molecules, respectively for Chagas Disease. Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Chagas Disease (American Trypanosomiasis) Overview 9 Therapeutics Development 10 Pipeline Products for Chagas Disease (American Trypanosomiasis) - Overview 10 Pipeline Products for Chagas Disease (American Trypanosomiasis) - Comparative Analysis 11 Chagas Disease (American Trypanosomiasis) - Therapeutics under Development by Companies 12 Chagas Disease (American Trypanosomiasis) - Therapeutics under Investigation by Universities/Institutes 13 Chagas Disease (American Trypanosomiasis) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Chagas Disease (American Trypanosomiasis) - Products under Development by Companies 17 Chagas Disease (American Trypanosomiasis) - Products under Investigation by Universities/Institutes 18 Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development 19 Bayer AG 19 Eisai Co., Ltd. 20 GlaxoSmithKline Plc 21 Grupo Praxis Pharmaceutical SA 22 KaloBios Pharmaceuticals, Inc. 23 Merck & Co., Inc. 24 Novartis AG 25 Sanofi 26 Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 benznidazol - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 benznidazole - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 chagas disease (bivalent) vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 chagas disease vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 chagas disease vaccine - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Chagas disease vaccine - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Cz-007 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Cz-008 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 EPLBS-1246 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 EPLBS-967 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 fexinidazole - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 fosravuconazole - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 GNF-6702 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 K-777 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 NEU-321 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 nifurtimox - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 nifurtimox SR - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 posaconazole - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SAR-114137 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecules for Chagas Disease - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Small Molecules for Chagas Disease - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecules for Chagas Disease - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Small Molecules for Chagas Disease - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Small Molecules for Chagas Disease - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecules for Infectious Diseases - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecules for Infectious Diseases - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecules for Protozoal Infections - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 VNI - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Chagas Disease (American Trypanosomiasis) - Dormant Projects 72 Chagas Disease (American Trypanosomiasis) - Discontinued Products 73 Chagas Disease (American Trypanosomiasis) - Product Development Milestones 74 Featured News & Press Releases 74 Apr 11, 2016: KaloBios Announces New Product Pricing Model 74 Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease 74 May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease 75 Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 76 Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 77 May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world 78 Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 79 Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 80 Appendix 81 Methodology 81 Coverage 81 Secondary Research 81 Primary Research 81 Expert Panel Validation 81 Contact Us 81 Disclaimer 82
List of Tables
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2016 10 Number of Products under Development for Chagas Disease (American Trypanosomiasis) - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H2 2016 19 Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co., Ltd., H2 2016 20 Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H2 2016 21 Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2016 22 Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 23 Chagas Disease (American Trypanosomiasis) - Pipeline by Merck & Co., Inc., H2 2016 24 Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H2 2016 25 Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H2 2016 26 Assessment by Monotherapy Products, H2 2016 27 Number of Products by Stage and Target, H2 2016 29 Number of Products by Stage and Mechanism of Action, H2 2016 31 Number of Products by Stage and Route of Administration, H2 2016 33 Number of Products by Stage and Molecule Type, H2 2016 35 Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2016 72 Chagas Disease (American Trypanosomiasis) - Discontinued Products, H2 2016 73
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
